Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks

Two under-$20 healthcare stocks, Viatris and BioCryst, have caught the attention of billionaire-led investors in the second quarter. Viatris (NASDAQ: VTRS), currently trading around $16 per share, has seen a slight decline in the number of billionaire funds holding its stock from 24 in the first quarter to 23 in the second. BioCryst (NASDAQ: BCRX), priced at approximately $10 a share, saw an increase in the number of funds holding its shares from 20 to 22 during the same period.

The article primarily focuses on Viatris, which is up about 33% so far this year. The company manufactures and sells generic drugs and off-patent branded medicines. Viatris' revenue for Q2 rose by 4.9% year over year, and the management has raised fiscal 2026 guidance across all key metrics. The FDA recently approved Gwyn Lo, a once-weekly contraceptive patch, earlier than the set deadline, and expects to launch the product later in fiscal 2026.

Additionally, a fast-acting version of meloxicam, a non-opioid painkiller, is still under review, with approval expected in the coming months. Viatris' forward non-GAAP P/E ratio is near 6.6, significantly lower than the sector median of 19.7, and its forward EV/EBITDA stands at approximately 7 compared to roughly 13. However, tariffs on Indian generics, which are largely imported by Viatris, pose a significant challenge, with many generic exemptions expiring in 2028.